Metabolic Mechanisms in Glioblastoma Therapeutics

Glioblastoma (GBM) is characterised by profound metabolic remodelling that supports rapid proliferation, invasion and therapy resistance. Tumour cells shift from mitochondrial oxidative phosphorylation to aerobic glycolysis, known as the Warburg effect, to generate both ATP and biosynthetic precursors. Parallel adaptations include rewiring of the tricarboxylic acid (TCA) cycle, enhanced lipid synthesis and turnover, and altered amino-acid metabolism. Such changes supply energy, maintain redox balance and sustain macromolecule production under the hypoxic, nutrient-poor microenvironment of the brain. Therapeutic strategies now aim to exploit these metabolic vulnerabilities by inhibiting key enzymes, perturbing lipid droplet dynamics, targeting mitochondrial function and combining metabolic agents with conventional radio- and chemotherapy. Preclinical studies demonstrate that dual targeting of central carbon metabolism and apoptotic regulators can induce synthetic lethality, while disrupting lipid utilisation or cholesterol synthesis sensitises GBM cells and stem-like populations to receptor tyrosine kinase inhibitors. By integrating metabolic inhibitors with existing regimens, there is potential to overcome intrinsic resistance, extend patient survival and reduce tumour recurrence.

Research from Nature Portfolio

Studies have illuminated the role of lipid metabolism as a driver of glioblastoma progression. Detailed lipidomic analyses reveal that GBM cells accumulate lipid droplets enriched in monounsaturated triglycerides, which fuel fatty-acid oxidation and bolster proliferation. Inhibition of key lipases within these droplets impairs tumour growth and highlights a novel lipid-droplet-mediated axis as a therapeutic target. In parallel, investigation of the mevalonate pathway shows that farnesyl diphosphate synthase is upregulated in GBM tissue and correlates with activation of oncogenic signalling networks. Genetic or pharmacological suppression of this enzyme induces apoptosis selectively in glioblastoma cells and diminishes sphere-forming capacity, underscoring the potential of targeting isoprenoid biosynthesis for anti-GBM therapy.

Metabolic Mechanisms in Glioblastoma Therapeutics publication trend

The graph below shows the total number of articles in metabolic mechanisms in glioblastoma therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Warburg effect: The preference of cancer cells for aerobic glycolysis over oxidative phosphorylation, even in the presence of oxygen, to generate energy and biosynthetic precursors.

Tricarboxylic acid (TCA) cycle: A mitochondrial metabolic pathway that oxidises acetyl-CoA to produce NADH, FADH₂ and ATP, linking carbohydrate, lipid and amino-acid metabolism.

Synthetic lethality: A strategy in which simultaneous perturbation of two genes or pathways leads to cell death, whereas inhibition of either alone is non-lethal.

Bcl-xL: An anti-apoptotic member of the Bcl-2 protein family that inhibits mitochondrial outer membrane permeabilisation and apoptotic cell death.

Lipid droplets: Intracellular organelles that store neutral lipids, such as triglycerides and cholesterol esters, which can be mobilised for energy production or membrane synthesis.

Mevalonate pathway: A biosynthetic route originating from acetyl-CoA that produces isoprenoids, cholesterol and other essential lipids; often upregulated in cancer.

References

1. OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma. JCI Insight (2024).
2. ALDH5A1/miR-210 axis plays a key role in reprogramming cellular metabolism and has a significant correlation with glioblastoma patient survival. Cancer Cell International (2024).
3. Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells. Pharmaceutics (2024).
4. Lipid accumulation and oxidation in glioblastoma multiforme. Scientific Reports (2019).
5. Metabolic Drivers of Invasion in Glioblastoma. Frontiers in Cell and Developmental Biology (2021).
6. Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness. Experimental & Molecular Medicine (2018).